Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
Kaminska K, Akrap N, Staaf J, Alves CL, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg Å, Pérez-Fidalgo A, Ditzel HJ, Bosch A, Honeth G.
Kaminska K, et al. Among authors: veerla s.
Breast Cancer Res. 2021 Feb 18;23(1):26. doi: 10.1186/s13058-021-01402-1.
Breast Cancer Res. 2021.
PMID: 33602273
Free PMC article.